Compare PLSE & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | BHC |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2015 | 1996 |
| Metric | PLSE | BHC |
|---|---|---|
| Price | $25.34 | $5.32 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $22.00 | $8.00 |
| AVG Volume (30 Days) | 351.3K | ★ 1.7M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 423.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,724,000,000.00 |
| Revenue This Year | $840.00 | $4.61 |
| Revenue Next Year | $287.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.56 | $4.41 |
| 52 Week High | $27.98 | $8.69 |
| Indicator | PLSE | BHC |
|---|---|---|
| Relative Strength Index (RSI) | 56.83 | 42.20 |
| Support Level | $17.58 | $4.93 |
| Resistance Level | $27.14 | $5.62 |
| Average True Range (ATR) | 1.88 | 0.21 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 67.93 | 13.46 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.